Purchase this article with an account.
M. W. Meyer, D. Dryja, S. Reichl, A. Meyer, R. Winter; Toxicity of Bevacizumab to Cultured Human Corneal Endothelial Cells in vitro. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1806.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyse the toxicity of bevacizumab (AvastinTM) to cultured human corneal endothelial cells in vitro. Bevacizumab is a monoclonal antibody, which binds to and inhibits all subtypes of vascular endothelial growth factor A (VEGF-A). VEGF is the main stimulus for neovascularization in the eye. Neutralization of VEGF is a therapeutical method to treat neovascular diseases such as macula degeneration, diabetic retinopathy or neovascular glaucoma. Therefore, bevacizumab is injected either intracamerally or intravitreally.
We used secondary cultures of human corneal endothelial cells. The cultures were treated with bevacizumab in different dosages (1,0 mg, 1,25 mg and 5 mg) for 72 hours under serum-free and serum-containing conditions. That corresponds to the usually injected intracameral and intravitreal or the four- to fivehold dosis. The toxicity was analysed by specific toxicity and vitality tests named CytoTox-ONETM and CellTiter BlueTM. The statistical analysis was performed by analysis of variance (ANOVA).
Using the toxicity and vitality tests we detected no toxicity of bevacizumab to cultured corneal endothelial cells. There were no significant differences between both the dosages and serum-free or serum-containing cultures.
No toxic effect of bevacizumab to corneal endothelial cells was detected. Therefore, we expect no damage of corneal endothelial cells by using bevacizumab in clinical practice.
This PDF is available to Subscribers Only